Navigation Links
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
Date:12/24/2007

BEIJING, Dec. 24 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced positive top-line results of completed Phase II clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine. The stratified, randomized, double-blind trial of the vaccine was designed to assess the safety and immunogenicity of the vaccine.

Sinovac received approval from the China State Food and Drug Administration (SFDA) in April 2007 to conduct Phase Ib and II trials of the H5N1 whole viron vaccine and Phase I and Phase II trials of the H5N1 split vaccine.

The Phase II trial of the H5N1 whole viron inactivated vaccine was conducted by Beijing Centers for Disease Control and Prevention. It included 402 volunteers, between the ages of 18 and 60, who were each vaccinated with two doses of 5 ug, 10 ug or 15 ug. The preliminary results of the trials suggested that each of the three dosages can induce varying degrees of immune response. In particular, the anti-HI seroconversion rate, the increasing GMT and protection rate of the H5N1 whole viron inactivated vaccines for the 10ug and 15ug dosages reached the EMEA evaluation standards of seasonal flu vaccines, which is an indication of good immunogenicity of the vaccine. The trial result did not show any serious adverse reaction among volunteers, suggesting the vaccine's good safety profile.

In addition, Sinovac recently completed the phase I clinical trial of the split H5N1 vaccine. The result of vaccinations on children, adults and elderly with candidate vaccines of different dosage indicated that the split H5N1 vaccine is safe for human use.

Mr. Weidong Yin, Chairman, President and CEO, stated, "We are very pleased with the achievements of our team that led to the development of a pandemic influenza vaccine. After Phase II clinical trials of the whole viron H5N1 vaccine, the vaccine dosages and schedule can now be determined. This accomp
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
(Date:10/2/2014)... Arbor, Mich. (PRWEB) October 02, 2014 ... working with Hile Creative to refine its marketing approach. ... — MS Bioworks serves researchers in the biological sciences, ... MS Bioworks has already seen substantial growth over the ... engage with current customers, the company plans to launch ...
(Date:10/2/2014)... Schlieren, Switzerland and Morgantown, West Virginia (PRWEB) October ... Inc. (OTCQB: PRGB ) and InSphero AG jointly ... on mass spectrometry imaging of InSphero’s 3D InSight™ ... InSphero and hosted members of InSphero’s scientific team ... of the microtissues. Protea has since developed workflows ...
(Date:10/2/2014)... October 02, 2014 At a time when ... Products has introduced a new kind of squeeze aimed ... is the Scienceware® Squeeze Rite™ Wash Bottle , catalog ... position within the bottle reduces the waste of reagents, solutions ... those liquids. , “Easier to squeeze when compared to standard ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3Hile Creative to Provide Copywriting and Graphic Design Services for MS Bioworks 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 3Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 4New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 3, 2011 Asmacure Ltee, a clinical-stage ... agonists for the treatment of asthma and other inflammatory ... as chief executive officer.  With a solid foundation established ... it progresses its lead compound, a potential new treatment ...
Cached Biology Technology:Reportlinker Adds Orthopedic Biomaterials, The World Market 2Reportlinker Adds Orthopedic Biomaterials, The World Market 3Reportlinker Adds Orthopedic Biomaterials, The World Market 4EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... criminals, requires evidence and witnesses; but on the scale ... easier said than done. A team of ... Arizona State University may soon change that. Under a ... a new way to close the gaps in the ...
... Sarasota FL., December 17, 2007 Researchers at ... of the EASE (Exhale Airway Stents for Emphysema) Trial, ... treatment that may offer a significant new, minimally-invasive option ... focuses on a procedure called airway bypass that involves ...
... latest American Chemical Society (ACS) News Service Weekly PressPac with ... News.,Please credit the individual journal or the American Chemical Society ... FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed for ... ARTICLE #1 FOR IMMEDIATE RELEASE A faster, ...
Cached Biology News:ASU researchers use NASA satellites to improve pollution modeling 2Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 3American Chemical Society's Weekly PressPac -- Dec. 12, 2007 4American Chemical Society's Weekly PressPac -- Dec. 12, 2007 5American Chemical Society's Weekly PressPac -- Dec. 12, 2007 6American Chemical Society's Weekly PressPac -- Dec. 12, 2007 7American Chemical Society's Weekly PressPac -- Dec. 12, 2007 8American Chemical Society's Weekly PressPac -- Dec. 12, 2007 9American Chemical Society's Weekly PressPac -- Dec. 12, 2007 10
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: